Real‐world treatment patterns and outcomes in a national study of veterans with Waldenström macroglobulinemia, 2006–2019

myelofibrosis. In conclusion, our observations from the current study do not support the consideration of ExT as a risk factor for thrombosis, in otherwise low-risk ET, and question the value of prophylactic cytoreductive therapy in the particular scenario; a similar observation was recently communicated regarding the use of hydroxyurea in ET patients age 40–59 years and without risk factors for thrombosis or platelet count ≥1500 × 10/L; a prospective controlled study is needed for further clarification and confirmation of the observed benefit from aspirin therapy in the current retrospective study.

[1]  A. Tefferi,et al.  Young platelet millionaires with essential thrombocythemia , 2021, American journal of hematology.

[2]  T. Barbui,et al.  Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk‐stratification and management , 2020, American journal of hematology.

[3]  S. Ferrero,et al.  Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies , 2020, American journal of hematology.

[4]  S. Treon,et al.  Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Juan Feng,et al.  Rituximab-based combination therapy in patients with Waldenström macroglobulinemia: a systematic review and meta-analysis , 2019, OncoTargets and therapy.

[6]  A. Tefferi,et al.  3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk‐Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups , 2018, Mayo Clinic proceedings.

[7]  A. Tefferi,et al.  Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger , 2018, American journal of hematology.

[8]  M. Dimopoulos,et al.  Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia , 2018, The New England journal of medicine.

[9]  M. Kersten,et al.  Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  R. Fonseca,et al.  Waldenström macroglobulinaemia , 2007, British journal of haematology.

[11]  A. Tefferi,et al.  Management of extreme thrombocytosis in otherwise low-risk essential thrombocythemia; does number matter? , 2006, Blood.

[12]  J. D. van der Walt,et al.  Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. , 2005, The New England journal of medicine.

[13]  T. Barbui,et al.  Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. , 1995, The New England journal of medicine.